Drug Injury Lawyers Also See Possible Farxiga And Jardiance Cases For Patients Who Have Ketoacidosis, Kidney Failure, Stroke, Or Heart Attack

 

(Posted by Tom Lamb at DrugInjuryWatch.com)
 

 ________________________________________________________________________________

UPDATE: “Health Canada Warns About Link Between DKA & Popular Diabetes Drugs“

(5/19/16)

 ________________________________________________________________________________

 

With there being a growing number of Type 2 diabetes patients in the US, it is not a surprise that the pharmaceutical companies are introducing new types of diabetes medications at an increasing rate to capture market share and make profits.

One new class of new diabetes medications are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, which currently consist of these drugs:

Invokana (canagliflozin) — first available in 2013
Invokamet (canagliflozin and metformin) — first available in 2014
Farxiga (dapagliflozin) — first available in 2014
Xigduo XR (dapagliflozin and metformin extended-release) — first available in 2014
Jardiance (empagliflozin) — first available in 2014
Glyxambi (empagliflozin and linagliptin) — first available in 2015

As some of you know, often the serious side effects of new drugs are not recognized until after FDA approval and they are used by a larger patient population than was observed or studied in the earlier clinical trials.

And this seems to be the case with Invokana, Farxiga, Jardiance, and these other new diabetes drugs, as there are now numerous adverse event report which associate them with these side effects:

• Diabetic Ketoacidosis (DKA), Ketoacidosis, or Ketosis
• Heart Attacks / Myocardial Infarctions (MI)
• Ischemic Stroke / Cerebral Vascular Accident (CVA)
• Kidney Damage / Renal Failure
• Heart Failure

________________________________________

Invokana / Farxiga / Jardiance
Free Case Evaluation
Strictly Confidential, No Obligation.

________________________________________

 

And, in fact, reports of side effects related to Invokana, Farxiga, and Jardiance have gotten the attention of the FDA and other drug regulators, as can be seen by the following recent drug safety alerts:

“FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood” (May 15, 2015)

Review of diabetes medicines called SGLT2 inhibitors started — European Medicines Agency (June 12, 2015)

“Information Update – Forxiga, Invokana: Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosis” (June 22, 2015)

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis — Medicines and Healthcare Products Regulatory Agency (June 26, 2015)

With these investigations by drug regulators there are, also, investigations by drug injury lawyers into possible lawsuits for people with Type-2 diabetes who used one of these SGLT2 diabetes drugs and developed ketoacidosis or kidney failure, as well as when these diabetics suffer a heart attack (MI), stroke (CVA), or heart failure.

We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed any of the medical conditions listed above.

 

DrugInjuryLaw.com: Legal & Medical Information About Drug Side Effects  (All website content by attorney Tom Lamb)

Drug Injury Case Evaluation – Free. Confidential. No Obligaion.  (Case review done by attorney Tom Lamb)